29 June 2020 | News
ImmuSAFE™ is a lab-based biochip test that utilises Sengenics’ patented KREX™ protein folding technology
Image credit- shutterstock.com
Singapore based Sengenics, the Functional Proteomics Company, has announced the launch of ImmuSAFE™ COVID+, a multi-antigen, multi-domain, fully quantitative serology test.
ImmuSAFE™ enables the determination of the target epitopes, titres and Ig class/sub-class (IgG, IgA, IgM; IgG1-4) of antibodies produced across all stages of COVID-19 infection, from initial exposure, disease development, post-recovery or post-vaccination.
These results will provide critical insights on whether individuals have high titres of potentially neutralising antibodies against SARS-CoV-2 that may protect against reinfection or whether booster vaccinations are required.
ImmuSAFE™ COVID+ will also enable quantitative assessment of patient response in vaccination trials, including differentiation of whether observed antibody responses are due directly to the vaccine or to prior SARS-CoV-2 exposure.
ImmuSAFE™ is a lab-based biochip test that utilises Sengenics’ patented KREX™ protein folding technology ensuring that viral antigens are correctly folded, preserving all conformational and linear antibody binding sites.
The test contains more than ten domains of SARS-CoV-2 Nucleocapsid and Spike proteins including full-length and numerous truncated versions.